PE20081693A1 - Derivados de cinolin-3-carboxamida como inhibidores de csf-1r - Google Patents

Derivados de cinolin-3-carboxamida como inhibidores de csf-1r

Info

Publication number
PE20081693A1
PE20081693A1 PE2008000185A PE2008000185A PE20081693A1 PE 20081693 A1 PE20081693 A1 PE 20081693A1 PE 2008000185 A PE2008000185 A PE 2008000185A PE 2008000185 A PE2008000185 A PE 2008000185A PE 20081693 A1 PE20081693 A1 PE 20081693A1
Authority
PE
Peru
Prior art keywords
csf
inhibitors
halo
amino
cinoline
Prior art date
Application number
PE2008000185A
Other languages
English (en)
Inventor
Leslie Dakin
Claude Afona Ogoe
David Scott
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39310013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081693(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20081693A1 publication Critical patent/PE20081693A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE R1 Y R2 SON CADA UNO H, HALO, NITRO, CIANO, HIDROXI, ENTRE OTROS; R3 ES H, HALO; m ES 0-1; R4 ES HALO, NITRO, CIANO, TRIFLUOROMETOXI, AMINO, CARBOXI,ETOXI, ENTRE OTROS; n ES 0-5. SON COMPUESTOS PREFERIDOS: 7-ETOXI-4-[(2-FLUORO-4-METIL-FENIL)AMINO]-6-(4-METILPIPERAZIN-1-IL)CINOLIN-3-CARBOXAMIDA; 4-[(2,4-DIFLUOROFENIL)AMINO]-7-METOXI-6-(4-METILPIPERAZIN-1-IL)CINOLIN-3-CARBOXAMIDA; ENTRE OTROS. REFERIDA TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE CSF-1R (FACTOR ESTIMULANTE DE COLONIAS 1) UTILES EN EL TRATAMIENTO DE CANCER
PE2008000185A 2007-01-25 2008-01-24 Derivados de cinolin-3-carboxamida como inhibidores de csf-1r PE20081693A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88658507P 2007-01-25 2007-01-25
US95157607P 2007-07-24 2007-07-24

Publications (1)

Publication Number Publication Date
PE20081693A1 true PE20081693A1 (es) 2009-01-18

Family

ID=39310013

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000185A PE20081693A1 (es) 2007-01-25 2008-01-24 Derivados de cinolin-3-carboxamida como inhibidores de csf-1r

Country Status (18)

Country Link
US (2) US7723337B2 (es)
EP (1) EP2118072A1 (es)
JP (1) JP2010500988A (es)
KR (1) KR20090111337A (es)
AR (1) AR065042A1 (es)
AU (1) AU2008208751A1 (es)
BR (1) BRPI0808005A2 (es)
CA (1) CA2675621A1 (es)
CL (1) CL2008000191A1 (es)
CO (1) CO6190614A2 (es)
EC (1) ECSP099539A (es)
IL (1) IL199911A0 (es)
MX (1) MX2009007889A (es)
PE (1) PE20081693A1 (es)
RU (1) RU2009131834A (es)
TW (1) TW200843775A (es)
UY (1) UY30880A1 (es)
WO (1) WO2008090353A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
US20110190272A1 (en) * 2008-05-07 2011-08-04 Astrazeneca Ab Chemical compounds
US9884828B2 (en) 2011-05-23 2018-02-06 Imago Pharmaceuticals, Inc. Substituted cinnolines as inhibitors of LRRK2 kinase activity
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
CN108884084A (zh) * 2016-03-21 2018-11-23 阿斯利康(瑞典)有限公司 噌啉-4-胺化合物及其在治疗癌症中的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621425D0 (en) * 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
DK273689A (da) * 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
JPH04211661A (ja) * 1990-03-28 1992-08-03 Otsuka Pharmaceut Co Ltd キノリン誘導体及び該誘導体を含有する抗潰瘍剤
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
PL359181A1 (en) 2000-07-07 2004-08-23 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
SE0101675D0 (sv) * 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
GB0322726D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
WO2006124996A2 (en) * 2005-05-17 2006-11-23 Supergen, Inc. Inhibitors of polo-like kinase-1
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
PT2010496E (pt) 2006-04-14 2010-10-13 Astrazeneca Ab 4-anilinoquinolina-3-carboxamidas como inibidores de csf-1r cinase
TW200829555A (en) 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
RU2009131834A (ru) 2011-02-27
EP2118072A1 (en) 2009-11-18
US20110098283A1 (en) 2011-04-28
US7723337B2 (en) 2010-05-25
CO6190614A2 (es) 2010-08-19
AR065042A1 (es) 2009-05-13
MX2009007889A (es) 2009-07-31
ECSP099539A (es) 2009-08-28
CA2675621A1 (en) 2008-07-31
TW200843775A (en) 2008-11-16
CL2008000191A1 (es) 2008-08-22
IL199911A0 (en) 2010-04-15
US20090012084A1 (en) 2009-01-08
UY30880A1 (es) 2008-09-02
BRPI0808005A2 (pt) 2013-07-30
JP2010500988A (ja) 2010-01-14
AU2008208751A1 (en) 2008-07-31
KR20090111337A (ko) 2009-10-26
WO2008090353A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20081693A1 (es) Derivados de cinolin-3-carboxamida como inhibidores de csf-1r
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
PE20061073A1 (es) Compuestos derivados de piperidinilamida como agentes inhibidores de quinasas
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
PE20121182A1 (es) Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
PE20130647A1 (es) Indoles
UY30051A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PA8632701A1 (es) Compuestos terapeuticos
PE20090772A1 (es) Derivados de bencimidazol
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
PE20080839A1 (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
PE20081806A1 (es) Imidazo- y triazolopirimidinas sustituidas
PE20080948A1 (es) Derivados de imidazol como moduladores de la senda de hedgehog
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
PE20091376A1 (es) Derivados de fenilamino como moduladores de beta-amiloide
PE20090770A1 (es) Derivados de benzoxazolona
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20040165A1 (es) Uso de analogos del benzimidazol en el tratamiento de la proliferacion celular
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
DE60328010D1 (de) Heterocyclische verbindungen
CR8749A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
MX2010005033A (es) Aminas heterociclicas fungicidas.

Legal Events

Date Code Title Description
FC Refusal